Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799043

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1799043

Solitary Fibrous Tumor Treatment

PUBLISHED:
PAGES: 279 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Solitary Fibrous Tumor Treatment Market to Reach US$54.6 Million by 2030

The global market for Solitary Fibrous Tumor Treatment estimated at US$43.9 Million in the year 2024, is expected to reach US$54.6 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$31.9 Million by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.0 Million While China is Forecast to Grow at 6.8% CAGR

The Solitary Fibrous Tumor Treatment market in the U.S. is estimated at US$12.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.0 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Solitary Fibrous Tumor Treatment Market - Key Trends & Drivers Summarized

Solitary Fibrous Tumor Treatment: Is Precision Oncology Changing the Paradigm?

Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that may be benign or malignant, and their unpredictable nature presents significant challenges in diagnosis, treatment planning, and long-term management. These tumors most commonly arise in the pleura but have also been identified in various extrapleural sites such as the meninges, abdomen, and extremities. A key trend in SFT management is the central role of histopathological analysis and immunohistochemical markers in improving diagnostic accuracy. The identification of the NAB2-STAT6 gene fusion as a genetic hallmark has significantly refined diagnosis and is increasingly used as a target for future therapies. Treatment protocols are evolving rapidly as institutions recognize the need for individualized approaches based on tumor grade, size, and metastatic potential.

Surgical resection remains the primary curative option for localized tumors, especially when negative margins are achieved. However, in cases of high-risk histological features or incomplete excision, adjunctive treatments such as radiotherapy and systemic therapies are being explored. There is growing interest in stereotactic body radiotherapy (SBRT) for localized but inoperable lesions, and in adjuvant radiation for margin-positive resections. Chemotherapy has shown limited efficacy, but combination regimens involving temozolomide, bevacizumab, and tyrosine kinase inhibitors are under investigation. Personalized oncology is also making its mark through genomic profiling and next-generation sequencing to uncover actionable mutations that could inform targeted therapies, particularly in recurrent or metastatic cases.

Are Emerging Therapies and Diagnostics Reshaping Patient Outcomes?

Recent advancements in molecular pathology and imaging are significantly improving the detection and stratification of solitary fibrous tumors. PET-CT, MRI with contrast, and dynamic contrast-enhanced imaging are becoming standard for staging and monitoring. Additionally, the development of circulating tumor DNA (ctDNA) assays and other liquid biopsy methods offer promise for non-invasive disease surveillance and early detection of recurrence. Immunotherapy, particularly checkpoint inhibitors, is also being evaluated in SFT patients with aggressive or unresectable disease profiles. While still in early phases, results are encouraging and have sparked multiple clinical trials worldwide.

Further, patient-specific treatment regimens based on molecular markers are driving a paradigm shift in how rare soft-tissue tumors like SFT are managed. Tumor boards and rare disease registries are facilitating multi-disciplinary discussions and improving outcomes through consensus-driven treatment planning. As more data becomes available from global SFT cohorts, researchers are developing risk-based algorithms to determine optimal surveillance intervals, surgical strategies, and adjuvant therapy options. Such data-driven personalization is transforming the therapeutic outlook for a condition that has long suffered from ambiguous treatment pathways.

What Is Fueling the Growth in This Niche Oncology Market?

The growth in the solitary fibrous tumor treatment market is driven by several factors related to improved diagnostic capabilities, rising awareness among clinicians, and advancements in targeted and precision medicine. One primary driver is the increasing availability and use of advanced diagnostic modalities that can accurately identify SFTs and differentiate them from histologically similar tumors. This has led to more accurate staging and earlier treatment initiation. Additionally, the integration of genomic tools into clinical practice has empowered oncologists to customize therapies based on tumor biology, resulting in better patient outcomes.

The establishment of dedicated sarcoma treatment centers and rare cancer networks is another critical factor. These specialized facilities not only enhance access to expertise and experimental therapies but also contribute to patient registries and clinical trial pipelines. An increase in research funding, particularly into rare cancers and soft-tissue sarcomas, is catalyzing drug development and expanding treatment options. Furthermore, as data accumulates from observational studies and long-term follow-ups, predictive models and treatment algorithms are helping clinicians make evidence-based decisions. Together, these elements are driving the development of a robust and evolving treatment ecosystem for SFT patients worldwide.

SCOPE OF STUDY:

The report analyzes the Solitary Fibrous Tumor Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Radiation Therapy Treatment, Adjuvant Chemotherapy Treatment); End-User (Ambulatory Surgery Centers End-User, Hospitals End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aadi Bioscience, Inc.
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Arog Pharmaceuticals
  • AVEO Pharmaceuticals
  • Bayer AG
  • BeOne Medicines (formerly BeiGene)
  • Bristol-Myers Squibb Co
  • Chia Tai Tianqing Pharma
  • Chugai Pharma France
  • CytRx
  • Epizyme, Inc.
  • Gradalis, Inc.
  • Incyte Corporation
  • Iovance Biotherapeutics
  • Nanobiotix (Nanobiotix SA)
  • Novartis AG
  • Philogen S.p.A.
  • Plus Therapeutics, Inc.
  • Telix Pharmaceuticals Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP39366

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Solitary Fibrous Tumor Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Clinical Recognition of Rare Tumors Spurs Research and Diagnostic Efforts in SFT
    • Rising Use of Targeted Therapy and Tyrosine Kinase Inhibitors Propels Drug Development for SFT
    • Expansion of Genomic Profiling and Tumor Marker Identification Strengthens Precision Medicine Approaches
    • Advanced Imaging Modalities Improve Early Detection and Surgical Planning for Solitary Fibrous Tumors
    • Growing Role of Immunotherapy in Soft Tissue Sarcomas Generates Pipeline Activity in SFT Space
    • Clinical Trial Expansion for Rare Tumors Opens Funding and Access to Experimental Therapies
    • Surge in Tertiary Oncology Centers Enhances Access to Multimodal SFT Treatment Protocols
    • Digital Pathology and AI-Based Histology Support Early and Accurate SFT Diagnosis
    • Increased Advocacy for Rare Cancer Awareness Drives Inclusion in National Cancer Registries
    • Combination Therapy Regimens and Off-Label Use Trends Expand Offshoot Markets for Adjunct Treatments
    • Global Collaboration in Rare Disease Research Supports Regulatory Acceleration and Orphan Drug Status
    • Minimally Invasive Surgical Advancements Propel Demand for Improved Preoperative Planning Tools
    • Real-World Evidence Generation and Biomarker Discovery Sustain Long-Term Research and Investment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Solitary Fibrous Tumor Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adjuvant Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adjuvant Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Adjuvant Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Solitary Fibrous Tumor Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Solitary Fibrous Tumor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Solitary Fibrous Tumor Treatment by Treatment - Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Solitary Fibrous Tumor Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Adjuvant Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Solitary Fibrous Tumor Treatment by End-user - Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Solitary Fibrous Tumor Treatment by End-user - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-User, Hospitals End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!